420 Lexington Avenue
Suite 350
New York, New York 10170
Telephone: 1.212.584.4180

Data References

Phase 1 Clinical Trial for Type 1 Diabetes on
Treg Program Investor Summary and Article Packet Treg Program Fact Sheet
Abstracts for Peer-Reviewed Literature
Baecher-Allan, C., et al., CD4+CD25high regulatory cells in human peripheral blood. J Immunol, 2001. 167(3): p. 1245-53.
Bennett, C.L., et al., The immune dysregulation, polyendocrinopathy, enteropathy, Xlinked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet, 2001. 27(1): p. 20-1.
Bluestone, J.A. and Q. Tang, How do CD4+CD25+ regulatory T cells control autoimmunity? Curr Opin Immunol, 2005. 17(6): p. 638-42.
Bonelli, M., et al., Phenotypic and Functional Analysis of CD4+CD25-Foxp3+ T Cells in Patients with Systemic Lupus Erythematosus. J Immunol, 2009. 182(3): p. 1689-1695.
Brunstein, C.G., et al., Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood,2011. 117(3): p. 1061-1070.
Cao, T., et al., Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells preventlethal xenogenic graft versus host disease (GVHD). Cell Immunol, 2009. 258(1): p. 65-71.
Carrier, Y., et al., Th3 Cells in Peripheral Tolerance. I. Induction of Foxp3-Positive Regulatory T Cells by Th3 Cells Derived from TGF-beta T Cell-Transgenic Mice. J Immunol, 2007. 178(1): p. 179-185.
Chiarini, M., et al., Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy. Multiple Sclerosis Journal, 2011.
De Santis, G., et al., Altered miRNA expression in T regulatory cells in course of multiplesclerosis. J Neuroimmunol, 2010. 226(1-2): p. 165-71.
Di Ianni, M., et al., Tregs prevent GVHD and promote immune reconstitution in HLA haploidentical transplantation. Blood., 2011. 117(14): p. 3921-8. Epub 2011 Feb 3.
Engler, J.B., et al., Unmasking of autoreactive CD4 T cells by depletion of CD25 regulatory T cells in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2011.
Fazekas de St Groth, B., et al., Flow cytometric detection of human regulatory T cells. Methods Mol Biol, 2011. 707: p. 263-79.
Golshayan, D., et al., In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood, 2007. 109(2): p. 827-835.
Goodman, W.A., et al., IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells. J Immunol, 2009. 183(5): p. 3170-3176.
Hartigan-O’Connor, D.J., et al., Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods, 2007. 319(1-2): p. 41-52.
Hippen, K.L., et al., Massive ex Vivo Expansion of Human Natural Regulatory T Cells (Tregs) with Minimal Loss of in Vivo Functional Activity. Science Translational Medicine, 2011. 3(83): p. 83ra41.
Hoffmann, P., et al., Only the CD45RA+ subpopulation of CD4+CD25 high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood, 2006. 108(13): p.4260-7.
Horwitz, D.A., S.G. Zheng, and J.D. Gray, The role of the combination of IL-2 and TGFbeta or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsets. J Leukoc Biol, 2003. 74(4): p. 471-8.
June, C.H. and B.R. Blazar, Clinical application of expanded CD4(+)25(+) cells. Semin Immunol, 2006. 18(2): p. 78-88.
Kawashiri, S.-Y., et al., CD4+CD25(high)CD127(low/-) Treg Cell Frequency from Peripheral Blood Correlates with Disease Activity in Patients with Rheumatoid Arthritis. The Journal of Rheumatology, 2011. 38(12): p. 2517-2521.
Levings, M.K. and M.G. Roncarolo, T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. J Allergy Clin Immunol, 2000. 106(1 Pt 2): p. S109-12.
Marek-Trzonkowska, N., et al., Administration of CD4+CD25highCD127− Regulatory T Cells Preserves β-Cell Function in Type 1 Diabetes in Children. Diabetes Care, 2012.
Mathian, A., et al., Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Annals of the Rheumatic Diseases, 2012. 71(7): p. 1227-1234.
Mendel, I. and E.M. Shevach, The IL-10-producing competence of Th2 cells generated in vitro is IL-4 dependent. Eur J Immunol, 2002. 32(11): p. 3216-24.
Putnam, A.L., et al., Expansion of Human Regulatory T Cells from Patients with Type 1 Diabetes. Diabetes, 2008: p. 1108-1168.
Sakaguchi, S., et al., Regulatory T cells: how do they suppress immune responses? Int. Immunol., 2009: p. dxp095.
Scalapino, K.J., et al., Suppression of Disease in New Zealand Black/New Zealand White Lupus-Prone Mice by Adoptive Transfer of Ex Vivo Expanded Regulatory T Cells. JImmunol, 2006. 177(3): p. 1451-1459.
Sumida, Y., et al., Preparation of functionally preserved CD4+ CD25high regulatory Tcells from leukapheresis products from ulcerative colitis patients, applicable to regulatory T-cell transfer therapy. Cytotherapy, 2008. 10(7): p. 698-710.
Takahashi, T., et al., Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking theiranergic/suppressive state. Int Immunol, 1998. 10(12): p. 1969-80.
Tamosiuniene, R., et al., Regulatory T Cells Limit Vascular Endothelial Injury and Prevent Pulmonary Hypertension. Circulation Research, 2011.
Tang, Q. and J.A. Bluestone, The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol, 2008. 9(3): p. 239-244.
Tang, Q., et al., In vitro-expanded antigen-specific regulatory T cells suppressautoimmune diabetes. J Exp Med, 2004. 199(11): p. 1455-65.
Thompson, J.A., D. Perry, and T.M. Brusko, Autologous regulatory T cells for the treatment of type 1 diabetes. Curr Diab Rep, 2012. 12(5): p. 623-32.
Tosiek, M.J., et al., CD4+CD25+Foxp3+ Regulatory T Cells Are Dispensable for Controlling CD8+ T Cell-Mediated Lung Inflammation. J Immunol, 2011 186:6106-6118.
Trenado, A., et al., Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. JImmunol, 2006. 176(2): p. 1266-73.
Trzonkowski, P., et al., First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- Tregulatory cells. Clin Immunol, 2009. 133(1): p. 22-6.
Trzonkowski, P., et al., Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy. Cytometry A, 2009. 75(3): p. 175-88.
Veldman, C., A. Nagel, and M. Hertl, Type I regulatory T cells in autoimmunity and inflammatory diseases. Int Arch Allergy Immunol, 2006. 140(2): p. 174-83.
Wildin, R.S., et al., X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet, 2001. 27(1): p. 18-20.
Wright, G.P., et al., Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proceedings of the National Academy of Sciences, 2009. 106(45): p. 19078-19083.
Yagi, H., et al., Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol, 2004. 16(11): p. 1643-56.
Zheng, S.G., et al., CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGFbeta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. JImmunol, 2004. 172(3): p. 1531-9.
Zheng, S.G., J. Wang, and D.A. Horwitz, Cutting Edge: Foxp3+CD4+CD25+ Regulatory TCells Induced by IL-2 and TGF-{beta} Are Resistant to Th17 Conversion by IL-6. J Immunol, 2008. 180(11): p. 7112-7116.

These links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by NeoStem, Inc. of any of the products, services or opinions of the corporation or organization or individual. NeoStem, Inc. bears no responsibility for the accuracy, legality or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.

NeoStem - Cell Therapy Development - Clinical